London (UK), Rehovot (IL), October 2nd, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
More than 80% of the Shareholders were present or represented by Proxy. The Shareholders voted unanimously for all the proposed resolutions and in particular, authorizing the Balance Sheet, reelecting the Board the Audit Committee and the Statutory Auditors, giving power to the Board of Directors to emit shares against investments and asking the nominated Option Committee to propose an option plan. We are grateful for the confidence thus given to Company management and Board of Directors.
About Vidac Pharma
Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.
Disclaimer
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.
Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
+972 (0)779300647